Therapy Areas: Vaccines
Inovio Pharmaceuticals' potential COVID-19 vaccine trial put on partial clinical hold by US FDA
28 September 2020 -

US biotechnology company Inovio Pharmaceuticals Inc's (Nasdaq:INO) planned mid-to-late-stage trial of its experimental COVID-19 candidate was put on partial clinical hold by the US Food and Drug Administration, which sought additional information, Reuters news agency reported on Monday.

According to Inovio Pharmaceuticals, it was working to address the agency's queries by October 2020, including on the vaccine delivery device, after which the US agency would have 30 days to decide whether the trial should proceed.

The company said the pause was not due to any side effects in its early-stage study of the vaccine, which is continuing.

In June 2020 Inovio Pharmaceuticals had reported encouraging results from an early-stage human trial of its experimental COVID-19 vaccine candidate, INO-4800.

Login
Username:

Password: